Articles related to LGBTQIA+ MEDICINE

Explore how neighborhood pharmacists are tackling the Gender-Affirming Care Guide’s difficulty of comprehension and application. The study provides a critical analysis of community pharmacists’ awareness and use of the Gender-Affirming Care Guide. Unveiled by the American Pharmacists Association and Human Rights Campaign in March 2021, the guide represents a pivotal tool for delivering competent and respectful care to transgender and gender-diverse patients. Nonetheless, reports on pharmacists’ familiarity with, and adherence to, the guide are currently lacking. To examine this, an anonymous survey, structured around the guide’s principles, was sent to 700 Ohio community pharmacists. Of the 688 recipients, a mere 12% responded, revealing a stark lack of awareness about the guide – only 10% knew of its existence. Moreover, their self-reported ability to define key terminologies varied widely. Indeed, 95% could correctly define “transgender,” but only 14% knew “intersectionality.” The report underscores the importance of adopting the guide’s suggested practices. Notably, it found that 61% collected patients’ preferred names, and 54% considered transgender, gender-diverse, or non-heterosexual patients during staff training. Nevertheless, less than half claimed their pharmacy software managed critical gender-related data effectively. Despite these shortcomings, the surveyed pharmacists displayed a substantial interest in learning more about the guide’s contents. […]

In this study, of the 118 transgender and gender nonbinary (TGNB) patients, one-third of participants reported misgendering (being addressed in the dental environment using the wrong name and pronouns). Although refusal of oral health care was uncommon in our sample of TGNB participants, more than half believed that their regular source of oral health care was unable to provide gender-appropriate care. Avoidance owing to gender identity was found to be substantially related to self-reported unsatisfactory dental health. Gender insensitivity, awkward interactions, avoidance of care, and a lack of gender-affirming practitioners were all common themes un participants’ oral health care experiences.

The question of whether, when, and how children and adolescents with gender dysphoria should be treated medically or surgically is contentious. Gender dysphoria in the United States is being treated with “gender affirming care,” which may include gonadotrophin releasing hormone analogues (GnRHa) to suppress puberty, oestrogen or testosterone to promote secondary sex characteristics, and surgical removal or augmentation of breasts, genitals, or other physical features. At the same time, several European countries have issued guidelines limiting medical intervention in minors and emphasizing psychological care. There is little doubt in the medical community that children in distress require care, but there are concerns about the rapid widespread adoption of interventions and calls for rigorous scientific review from all corners.

Sunlenca (lenacapavir), which comes in 300 mg tablets and a 463.5 mg/1.5 mL injection, provides doctors with a long-needed twice-yearly option for patients with complicated past treatment histories who would otherwise have few treatment options.

The American Journal of Psychiatry presents this review of the most compelling articles that were covered in 2022: The Molecular and Cellular Alterations That Underpin Psychiatric Illnesses Shared and Distinct Neurobiological Mechanisms of PTSD Cognitive Deficits in Long-Term Cannabis Users Longitudinal Outcomes of Duration of Untreated Psychosis Accelerating TMS in the Treatment of Depression Infant Brain Development, Fragile X Syndrome, and Autism Spectrum Disorder Combining Computational Modeling and Postmortem Human Brain Studies to Uncover Synaptic Variability Contributions to Cortical Gamma Oscillation From the AJP Residents’ Journal: Identity and Stigma

A trio of posters look at clinical effectiveness fostemsavir for multidrug-resistant patients, real-world efficacy of the dolutegravir/lamivudine combination as a switch strategy, and a newer drug in the pipeline, islatravir prodrug BRII-732.